.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have introduced a promising approach for liver fibrosis treatment using a novel nanotechnology platform. However, liver fibrosis acts as a dangerous precursor to cirrhosis in patients with chronic liver diseases. Consequently, current clinical options often fail due to systemic side effects or low tissue specificity. Therefore, to overcome these barriers, scientists developed the Lac-AGly nanoparticle system. This platform utilizes natural glycogen as a biodegradable backbone. Notably, researchers modified the glycogen with lactobionic acid to target asialoglycoprotein receptors (ASGPR) on hepatocytes. For instance, this modification ensures that the therapeutic payload reaches the intended site with high precision.
This system delivers small interfering RNA (siRNA) specifically designed to silence connective tissue growth factor (CTGF). Furthermore, the researchers achieved a 51.2% degree of amination on the glycogen backbone. This modification conferred efficient siRNA binding capacity. Specifically, the resulting nanocomplexes maintained a uniform spherical shape and an average particle size of 247.2 nm. Moreover, in vivo testing revealed remarkable results in animal models. In addition, the treatment reduced the collagen-positive area in the liver from 14.3% to just 3.1%. Consequently, this platform demonstrates significant potential for clinical translation. Overall, it offers a safe and effective way to achieve gene-silencing without harming healthy tissues.
The system uses lactobionic acid to recognize asialoglycoprotein receptors (ASGPR). These receptors are primarily expressed on the surface of hepatocytes. Therefore, the siRNA is delivered directly to the liver cells.
Connective tissue growth factor (CTGF) is a key protein that promotes the accumulation of collagen and scar tissue. Specifically, silencing this gene helps halt and reverse the fibrotic process.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a glycogen-based nanoparticle platform that targets hepatocytes to silence CTGF, significantly reducing liver fibrosis in vivo....
8 months ago
A recent study demonstrates that spinal oxygen sensors do not require mitochondrial electron transport to trigger sympathetic excitation during acute hypoxia, revealing new insights into how mitochondrial oxidative stress modulates autonomic tone in cardiovascular and neurological diseases.
Today
Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today
The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today
A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today
Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today
